The PharmaPhorum article, "Evolving with the Patient: Optimizing CAGT Post-Trial Long-Term Follow-Up," authored by IQVIA Biotech’s Erin Finot and IQVIA’s Barbara Arone, experts delve into the challenges faced during long-term follow-up (LTFU) studies for cell and gene therapies (CAGT). The article discusses requirements set forth by regulatory bodies like the FDA and EMA and the need for efficient data collection methods that can adapt to patients' evolving journeys and regulatory and technology changes.

Read the full article.

Contact us to learn how we can bring your advanced therapy to market.